Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?
作者信息
Ogawa Masahiro, Kanda Tatsuo, Moriyama Mitsuhiko
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
出版信息
Hepatobiliary Surg Nutr. 2019 Aug;8(4):423-425. doi: 10.21037/hbsn.2019.03.19.
Abstract
摘要
相似文献
1
Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?针对丙型肝炎病毒感染的直接作用抗病毒药物与肝细胞癌复发无关吗？
Hepatobiliary Surg Nutr. 2019 Aug;8(4):423-425. doi: 10.21037/hbsn.2019.03.19.
2
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
3
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
4
Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage?直接作用抗病毒药物用于丙型肝炎病毒感染及其与肝内胆管癌的关联：是否存在联系？
J Oncol Pharm Pract. 2019 Oct;25(7):1743-1748. doi: 10.1177/1078155218800147. Epub 2018 Sep 26.
5
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.直接作用抗病毒药物治疗后乙型肝炎病毒感染与肝细胞癌复发的关系
Indian J Gastroenterol. 2017 May;36(3):235-238. doi: 10.1007/s12664-017-0755-3. Epub 2017 May 30.
6
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
7
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.肝细胞癌的二级预防：直接抗病毒药物与聚乙二醇干扰素及未治疗队列的比较
J Viral Hepat. 2017 Jan;24(1):13-16. doi: 10.1111/jvh.12651. Epub 2016 Dec 1.
8
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?我们是否应该在治疗肝癌的同时治愈丙型肝炎病毒？
Liver Int. 2018 Dec;38(12):2108-2116. doi: 10.1111/liv.13918. Epub 2018 Jul 21.
9
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
10
Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.肝移植受者中丙型肝炎病毒直接作用抗病毒药物的移植前与移植后治疗：更多待解决的问题
Exp Clin Transplant. 2017 Feb;15(Suppl 1):1-5. doi: 10.6002/ect.mesot2016.L19.
本文引用的文献
1
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.直接作用抗病毒治疗与多中心北美队列研究中肝细胞癌的复发无关。
Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.
2
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response.持续病毒学应答后丙型肝炎病毒相关肝细胞癌
World J Hepatol. 2018 Dec 27;10(12):898-906. doi: 10.4254/wjh.v10.i12.898.
3
Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.预测 HCV 感染 DAA 治疗后 HCC 的极早期发生。
Hepatol Int. 2018 Nov;12(6):523-530. doi: 10.1007/s12072-018-9895-5. Epub 2018 Sep 21.
4
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
5
Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.丙型肝炎病毒感染失代偿期肝硬化患者的无干扰素治疗
Hepatol Int. 2017 Jan;11(1):38-44. doi: 10.1007/s12072-016-9749-y. Epub 2016 Jun 9.
6
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
7
8
Current management of patients with hepatocellular carcinoma.肝细胞癌患者的当前管理
World J Hepatol. 2015 Jul 28;7(15):1913-20. doi: 10.4254/wjh.v7.i15.1913.
9
APASL consensus statements and management algorithms for hepatitis C virus infection.亚太肝脏研究学会丙型肝炎病毒感染共识声明及管理算法
Hepatol Int. 2012 Apr;6(2):409-35. doi: 10.1007/s12072-012-9342-y. Epub 2012 Mar 1.
10
Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.荟萃分析：干扰素改善肝癌消融或切除术的疗效。
Aliment Pharmacol Ther. 2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x.
Zotero 插件